Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]FTT PET/CT in Metastatic Prostate Cancer
NCT05242744Phase 1Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Mar 2023
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]FluorThanatrace in prostate cancer (PCa), sponsored by Abramson Cancer Center. Primary endpoint: Measurement of effect size at 21 days. Started Mar 2023; status: recruiting.
02
Drugs
[18F]FluorThanatrace
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05242744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242744.